Table of Contents Author Guidelines Submit a Manuscript
Arthritis
Volume 2015 (2015), Article ID 784825, 7 pages
http://dx.doi.org/10.1155/2015/784825
Research Article

Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

1Department of Clinical Biochemistry, Copenhagen University Hospital at Køge, 4600 Køge, Denmark
2Department of Rheumatology, Copenhagen University Hospital at Køge, 4600 Køge, Denmark
3The Parker Institute, Department of Rheumatology, Copenhagen University Hospitals at Frederiksberg and Bispebjerg, 2000 Copenhagen F, Denmark
4Institute for Inflammation Research (IIR), Rigshospitalet University Hospital, 2100 Copenhagen, Denmark
5DANBIO registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Glostrup, 2600 Glostrup, Denmark
6Department of Rheumatology, Copenhagen University Hospital Glostrup, 2600 Glostrup, Denmark
7Department of Rheumatology, Odense University Hospital, 5000 Odense, Denmark
8Department of Rheumatology, Copenhagen University Hospitals at Frederiksberg and Bispebjerg, 2000 Frederiksberg, Denmark
9Department of Rheumatology, Copenhagen University Hospital at Gentofte, 2900 Gentofte, Denmark
10Department of Rheumatology, Copenhagen University Hospital at Holbæk, 4300 Holbæk, Denmark

Received 22 December 2014; Accepted 30 January 2015

Academic Editor: Alejandro Balsa

Copyright © 2015 Grith P. Eng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. C. Kapetanovic, and T. Saxne, “Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab,” Arthritis and Rheumatism, vol. 54, no. 12, pp. 3782–3789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. T. R. D. J. Radstake, M. Svenson, A. M. Eijsbouts et al., “Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 11, pp. 1739–1745, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Bartelds, C. L. M. Krieckaert, M. T. Nurmohamed et al., “Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during longterm follow-up,” The Journal of the American Medical Association, vol. 305, no. 14, pp. 1460–1468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Krieckaert, A. Jamnitski, M. T. Nurmohamed, P. J. Kostense, M. Boers, and G. Wolbink, “Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity,” Arthritis & Rheumatism, vol. 64, no. 12, pp. 3850–3855, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. A. van Schie, M. H. Hart, E. R. de Groot et al., “The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region,” Annals of the Rheumatic Diseases, vol. 74, no. 1, pp. 311–314, 2015. View at Publisher · View at Google Scholar
  6. K. Bendtzen, “Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?” Arthritis and Rheumatism, vol. 63, no. 4, pp. 867–870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Aletaha, T. Neogi, A. J. Silman et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2569–2581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Fransen, M. C. W. Creemers, and P. L. C. M. van Riel, “Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria,” Rheumatology (Oxford), vol. 43, no. 10, pp. 1252–1255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. L. L. Prevoo, M. A. van'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Fransen and P. L. van Riel, “The disease activity score and the EULAR response criteria,” Rheumatic Disease Clinics of North America, vol. 35, no. 4, pp. 745–757, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Lallemand, N. Kavrochorianou, C. Steenholdt et al., “Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists,” Journal of Immunological Methods, vol. 373, no. 1-2, pp. 229–239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Steenholdt, M. A. Ainsworth, M. Tovey et al., “Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease,” Therapeutic Drug Monitoring, vol. 35, no. 4, pp. 530–538, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Steenholdt, J. Brynskov, O. Ø. Thomsen et al., “Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial,” Gut, vol. 63, no. 6, pp. 919–927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Wolbink, M. Vis, W. Lems et al., “Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 3, pp. 711–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Aarden, S. R. Ruuls, and G. Wolbink, “Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement,” Current Opinion in Immunology, vol. 20, no. 4, pp. 431–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Bendtzen, “Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine,” Immunotherapy, vol. 4, no. 11, pp. 1167–1179, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Bendtzen, “Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists,” Discovery Medicine, vol. 15, no. 83, pp. 201–211, 2013. View at Google Scholar · View at Scopus
  19. S. Tatarewicz, J. M. Miller, S. J. Swanson, and M. S. Moxness, “Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics,” Journal of Immunological Methods, vol. 357, no. 1-2, pp. 10–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. Hart, H. de Vrieze, D. Wouters et al., “Differential effect of drug interference in immunogenicity assays,” Journal of Immunological Methods, vol. 372, no. 1-2, pp. 196–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Ducourau, D. Mulleman, G. Paintaud et al., “Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases,” Arthritis Research and Therapy, vol. 13, no. 3, article R105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. G. M. Bartelds, C. A. Wijbrandts, M. T. Nurmohamed et al., “Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 921–926, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. N. Maini, F. C. Breedveld, J. R. Kalden et al., “Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis,” Arthritis & Rheumatology, vol. 41, no. 9, pp. 1552–1563, 1998. View at Publisher · View at Google Scholar
  24. C. L. Krieckaert, M. T. Nurmohamed, and G. J. Wolbink, “Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner,” Annals of the Rheumatic Diseases, vol. 71, no. 11, pp. 1914–1915, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. van der Maas, B. J. F. van den Bemt, G. Wolbink, F. H. J. van den Hoogen, P. L. C. M. van Riel, and A. A. den Broeder, “Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study,” BMC Musculoskeletal Disorders, vol. 13, article 184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Jamnitski, G. M. Bartelds, M. T. Nurmohamed et al., “The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept,” Annals of the Rheumatic Diseases, vol. 70, no. 2, pp. 284–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. E. W. St. Clair, C. L. Wagner, A. A. Fasanmade et al., “The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 46, no. 6, pp. 1451–1459, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Pascual-Salcedo, C. Plasencia, S. Ramiro et al., “Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.,” Rheumatology, vol. 50, no. 8, pp. 1445–1452, 2011. View at Publisher · View at Google Scholar · View at Scopus